Next Phase Newsletter

A Venture Capital firm based in USA is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor.

The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data.

The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring its investment to fund clinical trials and regulatory approval.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global venture capital and commercial development firm based in the USA has raised five life science-focused venture funds its flagship Venture Capital business unit and is currently investing out of its fifth fund. In addition, the firm recently closed on a new fund that is investing in companies domiciled in Singapore, Hong Kong and China. The firm generally looks to support companies with lead assets that can reach high value inflection points in 3-4 years and will consider opportunities in US, Canada, Europe, Singapore, Hong Kong and China.

The firm is currently seeking companies developing therapeutics or medical technologies to treat true unmet medical needs. The firm is therapeutic area agnostic, although the firm has historically been most active in immunology, oncology, and rare diseases. The firm typically prefers to invest in Series A/B rounds with a preference for lead assets between 18 months pre-IND and Phase 2a. Within devices, the firm generally prefers to invest in later stage opportunities, particularly those devices that have received market approval with early revenue.

The firm does not have any specific requirements for a firm’s management team. The firm is an active investor and seeks a director or observer position on a company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A seed fund focuses on applied AI technologies, and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multi-family venture fund based in the US is an active investor in the medical device sector, and is interested in opportunities in the western United States. Initial investments are typically about $150,000 with the potential for follow-on investments totaling $1 million and may be structured as equity or as debt. In the recent past, the firm has allocated new investments at a rate of approximately one every two months. The firm offers support and expertise to portfolio companies but does not seek a board seat.

The firm is interested in medical technology and lab equipment, including electro-mechanical medical devices, active implantable devices, and surgical instruments. The firm invests only in companies that have already developed a prototype of their product,  filed a patent application and have animal data.

The firm seeks to invest in strong management teams with prior experience in the medical device industry. The firm prefers to make investments with the potential to exit within 3-4 years.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An active early-stage life science development group founded by a private company currently backs more than 15 programs and companies, based on technologies and assets developed internally or in-licensed from academic medical institutions. The most advanced company in the portfolio has completed a Series D round, and total investment across all technologies exceeds $150 million. The firm has a dual development strategy. The firm partners with academic inventors to found, manage, and develop companies to a point of exit or strategic partnering. When founding companies, the firm leverages non-dilutive grant funding where available alongside their investment group. The firm can also support early clinical-stage companies looking for financial and management support to perform clinical proof of concept studies; specifically a combination of investor funding and management support to round out the capabilities of the existing team. The firm and its affiliated investor groups have the ability to lead investment rounds of up to $20 million while also providing any required management support through its experienced team, including in preclinical, clinical and business development.

The firm invests across the biosciences space including Therapeutics, Diagnostics, and Medical Devices although the primary focus is on Therapeutics. The group is opportunistic in terms of subsectors and indications. Historically, the group has been active with companies developing novel therapeutics including drugs for defending against inhaled pathogenic threats, treatment of asthma, cancer, autoimmune diseases, and hearing loss, a biomedical assay platform technology, molecular diagnostics, antioxidant nanoparticles, robotic and imaging technologies, and cardiovascular devices.

The firm is interested in connecting with companies looking to generate clinical proof-of-concept data and that require funding as well as management support to complement the existing team. We are especially interested in companies that may have an interest in relocating to Houston.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical company based in Asia has annual sales of about $160 million with more than 600 employees. The firm’s current marketing portfolio are mostly made of branded products licensed in from overseas partners. For the R&D activity, the firm has several clinical pipelines in the area of CNS and oncology under clinical study in the US, Europe, and Korea. The firm is actively searching for innovative candidates and products around the world to incorporate into its pipeline. Additionally, the firm also seek promising biotech with innovative approach to add into its investment portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. The firm is also able to invest in a financing round, preferably series A or B. In terms of indications, the firm is interested in movement disorders, CNS, liver disease, and immunology. The firm is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in late non-clinical development stage as well as in early clinical development stage. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; the firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third-party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in USA with additional offices in China invests in early-stage life science ventures, from Seed to Series B, with Series A and Series B being the firm’s sweet spot. Typical size of investment ranges from $1-2M in seed stage companies, and $3-5M in venture round companies.  
The firm also has an advisory service that supports entrepreneurs to expand to the Chinese market, and the firm has multiple offices in China and needed expertise to support the entrepreneur’s vision. 

Currently, the firm is most interested in companies based in USA, Israel, and Western Europe, particularly companies in the Nordic region. 
 
The firm will consider therapeutics, medical devices, diagnostics, and life science tools. The firm is most interested in medical devices, and their interests include medtech and biotech combination products, novel methods of drug delivery, in vitro diagnostics (novel instruments and reagents), etc. The firm is interested in both 510K and PMA devices. Within therapeutics, the firm is more interested in clinical assets and typically do not look at pre-clinical companies unless the opportunity is compelling. Current main indication areas of interest for the firm are cardiovascular disease, oncology, and women’s health. 
 
The firm seeks to work with management teams who are passionate about their technology and dedicated to creating values for the larger community. Though the firm is able to support companies who are interested in entering the China market, having a China angle is not necessary for investment. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.